These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 30477198)

  • 21. Hematologic neoplasms: Dendritic cells vaccines in motion.
    Galati D; Zanotta S
    Clin Immunol; 2017 Oct; 183():181-190. PubMed ID: 28870867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready 'N Able to Improve Clinical Outcome?
    Willemen Y; Versteven M; Peeters M; Berneman ZN; Smits ELJ
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32012714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
    Batich KA; Swartz AM; Sampson JH
    Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cell gene therapy.
    Onaitis M; Kalady MF; Pruitt S; Tyler DS
    Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.
    Schijns V; Tartour E; Michalek J; Stathopoulos A; Dobrovolskienė NT; Strioga MM
    Cytotherapy; 2014 Apr; 16(4):427-39. PubMed ID: 24280238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electroporation as a method of choice to generate genetically modified dendritic cell cancer vaccines.
    Ahmed R; Sayegh N; Graciotti M; Kandalaft LE
    Curr Opin Biotechnol; 2020 Oct; 65():142-155. PubMed ID: 32240923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dendritic cell-based therapeutic cancer vaccines].
    Rizzo M; Alaniz L; Mazzolini GD
    Medicina (B Aires); 2016; 76(5):307-314. PubMed ID: 27723619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ex vivo pulsed dendritic cell vaccination against cancer.
    Gu YZ; Zhao X; Song XR
    Acta Pharmacol Sin; 2020 Jul; 41(7):959-969. PubMed ID: 32366940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cell vaccines for cancer immunotherapy.
    Timmerman JM; Levy R
    Annu Rev Med; 1999; 50():507-29. PubMed ID: 10073291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions.
    Verheye E; Bravo Melgar J; Deschoemaeker S; Raes G; Maes A; De Bruyne E; Menu E; Vanderkerken K; Laoui D; De Veirman K
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
    Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
    J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-Level Computational Modeling of Anti-Cancer Dendritic Cell Vaccination Utilized to Select Molecular Targets for Therapy Optimization.
    Lai X; Keller C; Santos G; Schaft N; Dörrie J; Vera J
    Front Cell Dev Biol; 2021; 9():746359. PubMed ID: 35186943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The performance and perspectives of dendritic cell vaccines modified by immune checkpoint inhibitors or stimulants.
    Ding J; Zheng Y; Wang G; Zheng J; Chai D
    Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188763. PubMed ID: 35872287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personalized dendritic cell vaccination in cancer therapy: An evidence-based research study.
    Hatzidaki E; Papasotiriou I
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S52-S58. PubMed ID: 37147983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skin-Grafting and Dendritic Cell "Boosted" Humanized Mouse Models Allow the Pre-Clinical Evaluation of Therapeutic Cancer Vaccines.
    Zeng B; Moi D; Tolley L; Molotkov N; Frazer IH; Perry C; Dolcetti R; Mazzieri R; Cruz JLG
    Cells; 2023 Aug; 12(16):. PubMed ID: 37626903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic-Cell-Vaccine-Based Immunotherapy for Hepatocellular Carcinoma: Clinical Trials and Recent Preclinical Studies.
    Jeng LB; Liao LY; Shih FY; Teng CF
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.